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Bi‐allelic TECPR2 variants have been associated with a complex syndrome with
features of both a neurodevelopmental and neurodegenerative disorder. Here, we
provide a comprehensive clinical description and variant interpretation framework
for this genetic locus. Through international collaboration, we identified 17 in-
dividuals from 15 families with bi‐allelic TECPR2‐variants. We systemically reviewed
clinical and molecular data from this cohort and 11 cases previously reported.
Phenotypes were standardized using Human Phenotype Ontology terms. A cross‐
sectional analysis revealed global developmental delay/intellectual disability, mus-
cular hypotonia, ataxia, hyporeflexia, respiratory infections, and central/nocturnal
hypopnea as core manifestations. A review of brain magnetic resonance imaging
scans demonstrated a thin corpus callosum in 52%. We evaluated 17 distinct var-
iants. Missense variants in TECPR2 are predominantly located in the N‐ and
C‐terminal regions containing β‐propeller repeats. Despite constituting nearly half
of disease‐associated TECPR2 variants, classifying missense variants as (likely) pa-
thogenic according to ACMG criteria remains challenging. We estimate a patho-
genic variant carrier frequency of 1/1221 in the general and 1/155 in the Jewish
Ashkenazi populations. Based on clinical, neuroimaging, and genetic data, we pro-
vide recommendations for variant reporting, clinical assessment, and surveillance/
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treatment of individuals with TECPR2‐associated disorder. This sets the stage for
future prospective natural history studies.
K E YWORD S
Human Phenotype Ontology, neurodevelopmental disorder, sensory autonomic neuropathy,
spastic paraplegia, TECPR2
1 | INTRODUCTION
TECPR2 belongs to the tectonin β‐propeller repeat‐containing protein
family and is implicated in the autophagy pathway (Oz‐Levi et al., 2013;
Stadel et al., 2015). Autophagy is critical to the development and
function of the central nervous system. Loss‐of‐function variants in
several genes of the autophagy pathway lead to both neurodevelop-
mental and neurodegenerative diseases (Ebrahimi‐Fakhari et al., 2016;
Menzies et al., 2017; Teinert et al., 2019).
In 2012, Oz‐Levi et al. identified the homozygous TECPR2 variant
c.3416del, p.(Leu1139Argfs*75) in five individuals from three Jewish
Bukharian families and classified the syndrome as a novel subtype of
hereditary spastic paraplegia (HSP) (SPG49; MIM# 615000) (Oz‐Levi
et al., 2012). To date, 11 individuals with bi‐allelic TECPR2 variants have
been reported (Covone et al., 2016; Heimer et al., 2016; Oz‐Levi
et al., 2012; Patwari et al., 2020; Zhu et al., 2015). All individuals showed
muscular hypotonia and most had global developmental delay followed
by intellectual disability. Only a subset of individuals displayed pro-
gressive spasticity as a characteristic HSP symptom. An autonomic and
sensory neuropathy with respiratory, gastrointestinal and cardiovascular
system involvement was present in a subset of individuals and central
apnea was found to account for a large part of the morbidity (Heimer
et al., 2016; Patwari et al., 2020).
Beside two founder variants (c.3416del, p.(Leu1139Argfs*75) in
the Jewish Bukharian background and c.1319del, p.(Leu440Argfs*19)
in the Jewish Ashkenazi background), likely derived as new variants
under a Clan Genomics hypothesis (Lupski et al., 2011), two other
truncating and three missense TECPR2 variants have been associated
with the disease. Expression analyses in cell lines transfected with the
p.(Leu1139Argfs*75) variant indicated escape from nonsense‐mediated
RNA‐decay (NMD) but the degradation of the truncated protein
(Oz‐Levi et al., 2012). Functional data is largely missing for other de-
scribed variants. This poses challenges for the interpretation of mis-
sense variants, for which normal expression of an altered protein is
expected. All variants have been reported based on the clinical overlap
but have yet to be scored through the five‐tier variant classification
system recommended by the American College of Medical Genetics
and Genomics (ACMG) (Richards et al., 2015). The lack of functional
data and reliable variant classification have prevented an estimation of
carrier frequencies and disease incidence, genotype‐phenotype
correlation analyses and the ability to make a genetic diagnosis in
novel cases.
Through international collaboration, we assembled a cohort of
28 individuals from 24 families of different ethnic backgrounds with
known/novel disease‐associated TECPR2‐variants. Based on a de-
tailed review of the published cases and comparison with the herein
described individuals, we provide a systematic quantitative clinical
synopsis based on Human Phenotype Ontology (HPO) (Köhler
et al., 2019). We provide recommendations for clinical management,
including surveillance and symptomatic treatment. Annotation and
classification of all disease‐associated variants according to the
current ACMG recommendations are provided (Richards et al.,
2015). Using public databases, we estimate carrier frequencies and
disease incidence. Based on this curated phenotype and genotype
data set, we propose a framework for reporting and validating
TECPR2 variant alleles.
2 | MATERIALS AND METHODS
2.1 | Editorial policies and ethical considerations
This study adheres to the principles set out in the Declaration of
Helsinki. The following Research Ethics Committee approved ge-
netic testing in research setting within the study: Ethical Commit-
tee of the Medical Faculty, Leipzig University (P1), Institutional
Review Board at Boston Children's Hospital (IRB‐P00033016; P2,
P4, and P5), Ethics Review Board of Technical University of Munich
(P3), Institutional Review Board of King Faisal Specialist Hospital
and Research Center (KFSRHC RAC# 2080006 and 2121053; P7,
P8, and P13), Institutional Review Board at University College
London (P14 and P15, SYNaPS cohort), East of England and South
Cambridge Research Ethics Committee (REC: 14/EE/1112) for
100,00 Genomes Project Protocol (P16), Institutional Review Board
at Baylor College of Medicine (H‐29697) and Comité Etico Cienti-
fico at Facultad de Medicina, and Clinica Alemana Universidad del
Desarrollo (P17). Genetic testing for P6, P9, P10, P11, and P12 was
performed in a diagnostic setting. The authors received and ar-
chived written consent of the legal guardians to publish genetic and
clinical data (P1 ‐ P17) as well as photographs, computed tomo-
graphy (CT) scan, and magnetic resonance imaging (MRI) images
(P1, P4, P6, P11, P13, P15, P16, P17).
2.2 | Cohort
All 17 individuals described herein (P1–P17) were recruited through
GeneMatcher (Sobreira et al., 2015) or personal communication, from
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different institutions in Germany, Israel, United States, Saudi Arabia, the
United Arab Emirates, Great Britain, Pakistan, and Chile. Genotypic
data from P3 and P13 were previously reported without a detailed
clinical description (P3: reported as CB‐DYS‐125 in Zech et al., 2020;
P13: reported as 09DG00835 (Shams Anazi et al., 2017)).
2.3 | Clinical spectrum
Molecular and clinical data were collected from the referring clinicians
using a standardized questionnaire. All affected individuals were eval-
uated by a pediatric neurologist and/or geneticist. Reports of brain MRI
scans were available from 15 individuals. Clinical terms were standar-
dized using Human Phenotype Ontology (HPO) terminology (Köhler
et al., 2019). Clinical features were grouped into six categories (pheno-
typical abnormalities of body and face, intellectual and social develop-
ment, neurological system, respiratory system, gastrointestinal system,
and diagnostic procedures). Detailed case descriptions for all included
individuals are provided in Supporting Information Files S1 and S2 (sheet
“clinical_table”).
2.4 | Genetic analyses
Genomic DNA was extracted using standard methods from periph-
eral blood samples of probands/parents. For P1, P16, and P17 con-
ventional karyotyping was performed and all individuals, except P4,
P14, P15, P16, and P17, received a chromosomal microarray. TECPR2
variants were identified by gene panel analysis (P13), exome (P14
and P15), trio exome (P1 to P6, P10, P17), quad exome (P7 and P8),
trio genome (P16), or targeted Sanger sequencing (P9, P11, P12). All
herein identified TECPR2 variants have been submitted to ClinVar
(Supporting Information File S3 sheet “TECPR2_variants”).
2.5 | Review of published cases
A PubMed search identified five publications (Covone et al., 2016;
Heimer et al., 2016; Oz‐Levi et al., 2012; Patwari et al., 2020; Zhu
et al., 2015) describing 11 individuals from nine families diagnosed
with TECPR2‐associated disease (searched on 2020‐09‐10). Pheno-
typic features were extracted from published reports using the same
questionnaire applied to novel cases.
2.6 | Variant annotation and scoring
Variants were standardized to the TECPR2 reference transcript
NM_014844.4 (GRCh37/hg19) using Mutalyzer 2.0.32 (Wildeman
et al., 2008) and annotated as described previously (Popp et al., 2017)
with up‐to‐date versions of all tools (Cingolani, Patel, et al., 2012;
Cingolani, Platts, et al., 2012; Freeman et al., 2018; Liu et al., 2013) and
scores (Jian et al., 2014; Rentzsch et al., 2019; Xiong et al., 2015) (for
details see Supporting Information File S1). All diagnostic TECPR2 var-
iants were subsequently reclassified (Supporting Information File S3
sheet “TECPR2_variants”) following ACMG guidelines (Richards
et al., 2015).
2.7 | Estimation of carrier frequencies from public
databases
We retrieved all TECPR2 variants from gnomAD (Karczewski et al., 2020)
and BRAVO (see Web Resources). These were annotated, scored, and
filtered for classification as (likely) pathogenic as described before to
calculate carrier frequencies (Hebebrand et al., 2019).
2.8 | Analysis of missense variant spectrum and
modeling of TECPR2 protein structure
The distribution of TECPR2 missense variants in the secondary protein
structure was compared to missense variants reported as homozygous in
public population databases and protein regions constrained for missense
variation were analyzed as described (Hebebrand et al., 2019). For
analysis of the tertiary structure, we used the GalaxyWEB pipeline (Heo
et al., 2013; Ko, Park, Heo, et al., 2012; Ko, Park, & Seok, 2012) to divide
TECPR2 protein sequence into modeling units, predict their structure,
and refine the top model. Protein data bank (PDB) format structures
(Popp & Neuser, 2020) were then used for visualization with a pipeline
using the Pymol software (Meyer et al., 2016) and missense clustering
analysis as described before (Hebebrand et al., 2019). For details, also see
Supporting Information Notes S1.
2.9 | RNA expression analysis for the TECPR2
variant c.2829del, p.(Asn944Thrfs*7) in P1
Messenger RNA (ribonucleic acid) from peripheral blood lympho-
cytes of P1 and both parents was used to generate complementary
DNA (cDNA). Monoallelic expression was analyzed with reverse
transcription polymerase chain reaction (RT‐PCR), and Sanger se-
quencing and TECPR2 expression were analyzed using quantitative
PCR (qPCR) (see details in Supporting Information File S1).
3 | RESULTS
3.1 | TECPR2 Variant Spectrum
Genetic analyses, including conventional karyotyping, chromosomal mi-
croarray analysis, and multigene panels (except for P13) were un-
remarkable in all novel cases. Seventeen distinct variants in TECPR2,
including nine truncating and eight missense variants, were identified. Of
these, five truncating and five missense variants have not been reported
previously (Figure 1a).
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3.2 | Founder variants
The first reported founder variant (Oz‐Levi et al., 2012) in the Jewish
Bukharian population c.3416del, p.(Leu1139Argfs*75) was identified in
the homozygous allelic state in five individuals from the literature and in
two cases in our cohort. Additionally, the variant was discovered in a
compound heterozygous state with the Jewish Ashkenazi founder
variant in one previously reported individual. Two previously reported
F IGURE 1 TECPR2 structure with variant distribution and computational scores. (a) Schematic of the TECPR2 protein with WD40 and
TECPR repeat units (WD40: green, TECPR: orange; based on Uniprot O15040) and three modeling units (“N‐terminal”: gray, “central”: white,
“C‐terminal”: purple) identified by GalaxyDom. Disease‐associated variants identified in the cohort are depicted toward the top. The length of
the segments corresponds to each variant's CADD score. Blue dots represent novel identified variants, black dots represent variants reported
in the literature, and green dots represent the founder variants. Gray dots downwards show homozygous variants from gnomAD, the dot size
represents the logarithm of the allele count. In the panel below, a generalized additive model shows the values of CADD PHRED v1.6 for all
possible missense variants in TECPR2 across the protein secondary structure. The red horizontal line marks the recommended cut‐off (20). (b)
Homology model of the N‐terminal domain (AA 1–357; gray) generated through the GalaxyTBM pipeline showing the 7‐bladed β‐propeller fold
typical for WD40 repeat. The position of missense variants identified in the individual P3 (Gly239) from our study and “Family E II‐1” (Thr189)
from the literature review are presented as red spheres. Both missense variants affect conserved residues in β‐propeller folds. (c) Lateral
overview of the homology model of the C‐terminal domain (AA 802–1411; blue) showing the two β‐propeller folds in the TECPR repeat unit.
The position of missense variants identified in the individuals P7 and P8 (Asp1000), P6 (Trp1140), P17 (Arg1336), and P3 (Ala1345) from our
study and “Family H I‐1” (Thr903) from the literature review and (Arg1379) from the Spanish water dogs (Supporting Information Notes S1 and
Figure S1) are presented as red spheres. The blue highlighted part of the protein structure in the middle panel is truncated by the most
downstream stop gained variant c.4103G>A, p.(Trp1368*) identified in P14 and contains the amino acid position described as pathogenic in
Spanish water dogs
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individuals and four cases in our cohort were homozygous for the
founder variant in the Jewish Ashkenazi population, c.1319del,
p.(Leu440Argfs*19). This variant was also found in a compound het-
erozygous state with a missense variant (Heimer et al., 2016) and an-
other truncating variant (in our cohort). The two founder variants are
located in exons 8 and 16, respectively. GnomAD minor allele fre-
quency (MAF) was 37/275,698 for c.1319del, p.(Leu440Argfs*19) and
2/247,472 for c.3416del, p.(Leu1139Argfs*75). There were no entries
for the homozygous occurrence of these variants in the reference po-
pulations with data available.
3.3 | Other truncating variants
Among the cases derived from the literature, one individual carried
compound heterozygous frameshift variants (c.774del, p.(As-
p259Metfs*44); c.1028_1032del, p.(Lys343Argfs*2)). Novel identified
truncating variants were c.571C>T, p.(Gln191*) (homozygous), c.694dup,
p.(Thr232Asnfs*15) (homozygous), c.2829del, p.(Asn944Thrfs*7) (homo-
zygous), c.3830del, p.(Asn1277Thrfs*43) (compound heterozygous with
Ashkenazi founder variant) and c.4103G>A, p.(Trp1368*) (homozygous).
The variants are located in exons 5, 6, 7, 12, 18, and 20. MAF in the
heterozygous state was consistent with ultrarare variant alleles (Hansen
et al., 2019) and between 0 and 2/251,490 (gnomAD).
3.4 | Expression analysis of the stop codon
containing transcript in P1
Sanger sequencing of cDNA showed comparable detection of the
normal allele and the allele with the c.2829del, p.(Asn944Thrfs*7)
variant in both carrier parents of individual P1 (Figure 2a). Ad-
ditionally, RT‐PCR indicated normal expression in individual P1 who
is homozygous for the variant (Figure 2b). Comparable expression of
TECPR2 in individual P1, his parents, and in‐house controls was
confirmed by qPCR (Figure S3).
3.5 | Missense variants
To date, only three disease‐associated missense variants have been
reported (c.566C>T, p.(Thr189Ile); c.2050C>G, p.(Leu684Val);
c.2708C>T, p.(Thr903Met)). Novel variants identified include three
homozygous missense variants c.2998G>T, p.(Asp1000Tyr), c.3418T>G,
p.(Trp1140Gly) and c.4006C>T, p.(Arg1336Trp) as well as two com-
pound heterozygous missense variants c.715G>A, p.(Gly239Arg) and
c.4033G>C, p.(Ala1345Pro). All variants are predicted to be deleterious
by multiple in silico prediction programs except for the previously de-
scribed variant c.2050C>G, p.(Leu684Val) (CADD PHRED v1.6: 5.5;
mean for all reported missense: 24.4). For a complete overview of in
silico analyses please refer to Supporting Information File S3. Similar
results were obtained for the MAF, which is between 0 and
21/282,852, again except for c.2050C>G, p.(Leu684Val), which showed
an MAF of 11,974/282,150. In addition, this variant is found homo-
zygous in gnomAD (440x).
Analysis of spatial distribution in the linear protein structure in-
dicated that missense variants identified in the bi‐allelic state in in-
dividuals with TECPR2‐associated disease are predominantly located in
the N‐terminal (amino acid (AA) 1–357) and C‐terminal (AA 802–1411)
protein regions. These two regions display a higher restrain for missense
variation as indicated by higher computational scores and depletion of
homozygous missense variants (Figure 1a and S1).
This finding is further supported by the missense variant de-
scribed in Spanish water dogs (Hahn et al., 2015), which is highly
conserved (CADD PHRED score v1.6: 27.2) and located near to the
c.4033G>C, p.(Ala1345Pro) variant (P3) in the C‐terminal region;
also the amino acid residue affected by this variant is truncated by
the late stop variant c.4103G>A, p.(Trp1368*) identified in P14 (see
Supporting Information Notes S1 and Figure S1).
Our spatial proximity analysis using predicted 3D protein struc-
tures failed to identify clusters of missense variants (Table S3) but
showed that all affect highly conserved residues in the repeats
forming the N‐terminal 7‐bladed WD40 β‐propeller or the two pre-
dicted C‐terminal β‐propeller structures (Figures 1b,c and S2). While
we choose the GalaxyTBM (Ko, Park, & Seok, 2012) model for vi-
sualization of the spatial missense distribution in Figure S1, the
structural similarity of the model predicted de novo by the trRosetta
algorithm (Yang et al., 2020) is remarkable (Figure S2 and Table S2).
This convergence of structure prediction algorithms add confidence to
the derived models and will thus accelerate our understanding of
missense variants in genetic disorders lacking experimentally derived
protein structures.
3.6 | Carrier frequency for (likely) pathogenic
TECPR2 variants
Our results indicate that at least 1 in 1221 individuals (0.082%) in
gnomAD and 1 in 1610 individuals (0.062%) in BRAVO is a carrier
of a (likely) pathogenic variant in TECPR2. In gnomAD, we were able
to estimate the carrier frequency for eight subpopulations, which
ranged from 1 in 155 (0.650%; Jewish Ashkenazi) to 1 in 7654
(0.013%; South Asian). Using these frequencies, the expected in-
cidence is at least 1 in 5,961,640 newborns (based on gnomAD) to 1
in 10,366,419 newborns (based on BRAVO). Of the analyzed po-
pulations (which did not include the Jewish Bukharian population)
the highest incidence is expected in the Jewish Ashkenazi popula-
tion with 1 in 95,864 newborns.
3.7 | Predicted tertiary TECPR2 protein structure
The three different protein modeling algorithms that we have used
(Popp & Neuser, 2020) indicated similar results for the overall
TECPR2 tertiary structure. The N‐terminal domain (AA 1–357)
containing seven WD‐repeats is predicted to form a 7‐bladed
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β‐propeller fold (WD40 domain) with high similarity in all models
generated. The central region (AA 358–801) could either not be
modeled completely due to a lack of template structures or resulted
in unstructured and highly diverging models. The C‐terminal domain
(AA 802–1411), containing the six TECPR‐repeats annotated from
UniProt, was predicted to form a double β‐propeller motif in most
models with good structural similarity and five to seven blades per
propeller. Overall, this indicates a structured C‐terminal WD40‐
domain and TECPR‐repeat containing a structured double
β‐propeller motif in the C‐terminus, linked by a 444 AA long un-
structured peptide (Figures 1b,c and S2).
3.8 | Clinical spectrum
In our cohort of newly diagnosed cases, 11 of 17 individuals were
male. Age at last follow‐up was between 16 months and 15 years
with a mean of 65.2 ± 43.7 (SD) months. Consanguinity was reported
in 7 out of the 15 families. Five families were of Jewish Ashkenazi
descent, two families were of Jewish Bukharian. Except for P1, all
individuals were born at term without significant pre‐ or perinatal
complications. Three individuals were small for gestational age. Head
circumference at birth was generally within normal limits. At last
follow‐up, only seven individuals displayed short stature with a
height below −2 SD from age‐matched controls, however, all 11 in-
dividuals with data available were below average height. Brachyce-
phaly and microcephaly were observed in seven and four individuals,
respectively, with three individuals presenting both. Distinct facial
features were seen in 11 individuals though were not uniform.
Shared characteristics included a short neck, synophrys and a
triangular‐shaped face, still a recognizable pattern, or facial gestalt,
was not appreciated. Skeletal abnormalities, including significant
lumbar kyphosis, a barrel‐shaped chest, or hyperextension of the
neck were present in five cases.
The ages at diagnosis in our cohort ranged between 13 months and
15 years with a mean of 55.6 ± 48.8 (SD) months. All affected individuals
showed global developmental delay and later intellectual disability (DD/
ID) in the mild (n=1), moderate (n=7), and severe (n=8) ranges. P2 had
only mildly delayed gross motor skills at the last investigation, but her
young age rendered a detailed assessment difficult. Six individuals with
moderate or severe development delay were reported to have beha-
vioral dysregulation with hyperactivity, restlessness, and aggressive
F IGURE 2 Exemplary Sanger sequences, RT‐PCR, and CMA results for P1. (a) Chromatograms of DNA (Sanger sequencing) and RNA
(RT‐PCR on PAXgene stabilized blood) of P1 (down left) and his parents (up left and right). (b) Gel electrophoresis of cDNA‐amplicon. (c) CMA
data for individual P1 showing an unremarkable copy number of chromosome 14 (Log2Ratio top) and SNP allele peak distribution (AllelePeaks
bottom) showing a 6.52 Mb run‐of‐homozygosity (blue) containing TECPR2 (red). cDNA, complementary DNA; CMA, chromosomal
microarray; RT‐PCR, reverse transcription polymerase chain reaction; SNP, single‐nucleotide polymorphism
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behaviors. Two received a formal diagnosis of autism spectrum disorder.
Ten children (age range: 16 months to 8 years) had not started walking at
the time of the last follow‐up and 7 individuals walked independently
(mean age: 40.5 ± 36.2 (SD) months). P3 was diagnosed with dystonic/
dyskinetic cerebral palsy and started walking around the age of 10 years.
Speech development was delayed in all children and speech remained
limited to a few words with five individuals remaining completely
nonverbal.
The most common neurological manifestations in our cohort
included axial and appendicular hypotonia (17/17) accompanied by
gait ataxia (11/11), hyporeflexia of the lower limbs (13/17), and
dysarthria (6/8). Autonomic dysfunction, for example, temperature
instability (3/14) and hyperhidrosis (2/14) were noticed in a subset of
cases (5/15). Four individuals were reported to have impaired pain
sensation (4/16). Febrile seizures were found in P1 as well as P10;
P13, P14, and P15 were reported to have medically refractory epi-
lepsy and peripheral neuropathy was diagnosed in P6. Hearing im-
pairment (3/13) and visual impairment (5/12) were present in a
subset. The constellation of central respiratory dysregulation, dys-
phagia, and neuromuscular‐derived respiratory insufficiency was
common, resulting in central nocturnal (8/13) and/or daytime (5/16)
hypoventilation, dysphagia (9/17), and impaired clearance of secre-
tions. This was complicated by recurrent respiratory infections (14/
15), aspiration events (10/15), gastroesophageal reflux disease (9/
15), necessitated noninvasive positive pressure ventilation (i.e.,
nocturnal BiPAP) (2/13), and utilization of gastrostomy tubes (6/11)
in a subset. Airway malformation, such as laryngeal cleft or lar-
yngomalacia, was identified in a subset (4/17). Five individuals (5/15)
were reported to have chronic and significant constipation.
Clinical manifestations of previously reported individuals are sum-
marized in Supporting Information File S2. One case (Covone et al., 2016)
was excluded from further analysis since the variant c.2050C>G,
p.(Leu684Val) was classified as likely benign according to ACMG criteria.
In summary, manifestations shared by the majority of all 27 individuals
include Global development delay and intellectual disability (26/26,
100%), muscular hypotonia (27/27, 100%), hyporeflexia of the lower
limbs (22/27, 83%), and gait ataxia (19/19, 100%). Peripheral neuropathy,
dysarthria, and abnormal facial features were found in 9/12 (75%), 12/14
(86%), and 19/25 (76%) of individuals with sufficient data available
(Table 1). Recurrent respiratory infections (23/25, 92%), gastro-
esophageal reflux in infancy (18/25, 72%), and nocturnal hypoventilation
(12/17, 71%) affected most individuals.
3.9 | Brain imaging and EEG
A review of 16 brains' MRI studies from our cohort (Figures 3
and S4) and a review of reported cases in the literature defined a thin
corpus callosum as a common feature (11/21, 52%). Additional
findings in a subset of individuals included mild ventriculomegaly
(often asymmetric colpocephaly), delayed myelination, and diffuse
cerebral atrophy. EEG (electroencephalogram) was abnormal in four
cases (4/15, 27%), but no specific pattern was reported.
4 | DISCUSSION
We here report a series of 17 individuals with bi‐allelic TECPR2 variants
from eight nonconsanguineous families and nine consanguineous families
and combine the detailed clinical, imaging, and molecular characterization
of these individuals with the 11 cases previously reported. Since the
variant c.2050C>G, p.(Leu684Val) was classified as likely benign ac-
cording to ACMG criteria, one previously reported case (Covone
et al., 2016) was excluded. The girl's different clinical presentation
without developmental delay, autonomic nervous system involvement or
abnormal facial shape supports the variant assessment. Additionally, an
inherited variant of unknown significance in SPG7 was reported as an
additional genetic finding (Covone et al., 2016). The analysis of the re-
maining 27 individuals defines a core set of clinical and molecular fea-
tures. These consist of global developmental delay and intellectual
disability, axial and appendicular hypotonia, dysarthria, and an abnormal
gait, often described as an ataxic gait. Peripheral neuropathy was found
in two‐thirds of all individuals in whom a detailed neurological assess-
ment was available. Along with this, hyporeflexia was common and signs
of autonomic dysfunction were prominent in the majority of cases. The
latter included central hypoventilation, impaired temperature, and blood
pressure regulation, repeat aspiration events, and evidence of abnormal
gastrointestinal motility. These features imply the involvement of both
the central and peripheral nervous systems and substantiate features of
hereditary sensory and autonomic neuropathy (HSAN).
Whereas spasticity was recognized as a hallmark feature in the
individuals initially reported (Oz‐Levi et al., 2012), the overall pre-
valence of spasticity was limited to a subset in our analysis (24%).
We recognize that this is a potentially age‐dependent manifesta-
tion since increased tone was mainly reported in older individuals
(P3 at age 15 years; Family B II‐2 at age 20 years). P3 stands out
because of the presence of dystonia, which was not present in pre-
viously published cases and possibly further broadens the spectrum
of neurological symptoms. Of note, epilepsy was relatively infrequent
in our cohort and consisted of two individuals who experienced
febrile seizures, two previously reported siblings with infrequent
generalized tonic‐clonic seizures and three individuals with medically
refractory seizures. Future studies will be necessary to reassess
epilepsy as an associated feature. Overall, the wide neurological
manifestations in individuals with TECPR2‐associated disease along
the age spectrum, point to an involvement of multiple areas of the
central nervous system (i.e., cortico‐spinal tracts, cerebral cortex,
brain stem, possibly basal ganglia) as well as the peripheral nervous
system.
A large part of the morbidity and mortality associated with
TECPR2 results from central hypoventilation requiring therapy with
noninvasive positive pressure ventilation and occasionally active
mechanical ventilatory support. Our findings are supported by a
recently published, detailed analysis of the distinct breathing pattern
from one affected individual (Patwari et al., 2020).
Based on our clinical experience and the reported disease
manifestations, we suggest a framework for routine surveillance as
detailed in Table 2. Symptomatic treatment should be tailored to
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each individual case and aims at preserving function and preventing
long‐term morbidity and mortality. Early developmental support
should be maximized to harness the developmental potential.
Overall, our cross‐sectional analysis suggests that there is evi-
dence of disease progression from a predominantly neurodevelop-
mental disorder with global developmental delay and hypotonia in
early childhood to progressive disease with corticospinal and corti-
cobulbar dysfunction later in life. We know from personal commu-
nications about the disease course of previously reported patients
(Heimer et al., 2016; Oz‐Levi et al., 2012), who all lost the ability
to walk.
Due to largely nonspecific initial clinical features, individuals
with TECPR2‐associated disease may initially receive a diagnosis of
cerebral palsy. In addition to an often unremarkable perinatal his-
tory, clinical features that help distinguish TECPR2‐disease from
cerebral palsy include the findings of central apnea/hypoventilation,
autonomic instability, hyporeflexia as well as other signs of periph-
eral neuropathy. Brain MRI in TECPR2‐associated disease shows a
F IGURE 3 MRI and facial features of individuals with TECPR2‐associated disease. (a) T1 axial and sagittal images of P1 at the age of
four years show delayed myelination, mild ventriculomegaly, and periventricular gliosis. T1 axial and sagittal images of P4 at the age of one year
show mild thinning of the posterior corpus callosum and/or mildly hypoplastic corpus callosum with mild lateral ventriculomegaly. T1 axial and
sagittal images of P11 at the age of 2 years show thin corpus callosum, dysmorphic ventricles, and mild cerebral and cerebellar atrophy.
T1 axial and sagittal images of P13 at the age of 8 years show thinning of the corpus callosum and cerebellar vermis mild atrophy. T1 axial and
sagittal images of P16 at the age of 2 years show dysmorphic ventricles and a reduction in white matter volume. T1 axial and sagittal images of
P15 at the age of 3 years show rounded posterior horns of the bilateral lateral ventricles, cerebral, and mild cerebellar atrophy. (b) Facial
images of P1 (5 years 4 months), P4 (4 years front, 7 years lateral), P11 (4 years front, 3 years lateral), P13 (8 years), P16 (5 years), and P17
(10 years 11 months). Individuals with both facial and MRI are ordered vertically in (a) and (b); the dotted line indicates that for P15 only
MRI images are shown while for P17 only facial images are shown. MRI, magnetic resonance imaging
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thinning of the posterior parts of the corpus callosum in about half of
individuals. This finding can help guide diagnostic testing.
A diagnosis is achieved through molecular testing. With the identi-
fication of novel truncating and missense variants, we confirm and
broaden the spectrum of disease‐associated variants in TECPR2‐
associated hereditary sensory and autonomic neuropathy with in-
tellectual disability. All individuals in the cohort with distinct ethnic ori-
gins carried the respective founder variant. This observation affirms the
expected genotypic trait in the Jewish Ashkenazi and Jewish Bukharian
populations. However, the identification of other truncating variants
provides evidence for the occurrence of TECPR2‐associated disease in
other ethnic groups. For all families with homozygous variants other than
the founder variants, consanguinity of the parents was reported. This is
exemplified for P1 where the run‐of‐homozygosity on chromosome 14
was not described in the CMA report because it was below the 10 Mb
(mega base) filtering cutoff (Figure 2c). Similar results were reported for
P2 and P16 (Supporting Information File S1).
Our analysis did not show clustering or specific distribution
pattern of the truncating variants. RNA analysis of the novel fra-
meshift variant c.2829del, p.(Asn944Thrfs*7), identified in P1, in-
dicated escape from nonsense‐mediated decay. This argues against
NMD and is in line with previous results in cell lines showing no
effect on mRNA levels for the Jewish Bukharian variant c.3416del,
p.(Leu1139Argfs*75) (Oz‐Levi et al., 2012), but instead the resulting
truncated protein being targeted for proteasome‐mediated de-
gradation after translation.
In contrast, all disease‐associated missense variants in this co-
hort affect conserved residues in repeats forming the blades of β‐
propeller structures at the C‐terminal and the N‐terminal ends of the
protein (Figure 1). As we could not identify clustering in the tertiary
structure, misfolding and subsequent degradation could cause loss of
the protein carrying these missense substitutions. All five individuals
from our cohort harboring missense variants showed moderate to
severe DD/ID and are as severely affected as individuals with trun-
cating variants. Therefore, our data do not indicate milder clinical
manifestations in carriers of missense variants. This clinical ob-
servation further supports a similar pathomechanism, for example,
degradation of truncated or misfolded proteins, for both truncating
and missense variants. However, due to the currently limited
knowledge about TECPR2 function and lack of well‐established and
readily available functional tests, in most cases, missense variants
cannot be classified as (likely) pathogenic according to ACMG
guidelines. Based on our computational analyses, we propose to
consider the following criteria for the interpretation of TECPR2
missense variants: (1) variant position in the functional domains
identified through our conservation and modeling analyses
(PM1_Supporting; Figures 1a, S1, and S2), (2) deleterious effect
predicted by in silico CADD score with cutoff >20 (PP3; Figure 1a),
(3) the patient's phenotype matches the core features as well as
TECPR2‐specific symptoms of the HSAN‐spectrum (Table 1) and
exome‐wide analyses do not reveal other clinically relevant findings
(PP4), and (4) cosegregation of the identified variants with multiple
TABLE 2 Recommendations for
surveillance and symptomatic treatment Every 6 months Every 12 months
• Neurological examination, including a
developmental assessment
• Pulmonologist evaluation
• Gastroenterological evaluation and
consultation with a dietician
• Consider orthopedic evaluation
• Consider venous blood gases
• Consider BERA test (once in case of a
suspect for hearing impairment)
• Polysomnography study
• Consider chest X‐ray
• Consider mucous culture
• Consider spine X‐ray
• Consider swallowing study (unless fed by
gastrostomy)
• Consider echocardiography for signs of
pulmonary hypertension
• Consider blood pressure monitoring
• Consider arterial blood gases
• Fasting glucose, electrolytes, and liver
function tests (also during intercurrent
illnesses)
• Consider ENT evaluation if snoring or
consistent tonsillar enlargement
Supportive therapy—recommendations
Routine treatments by a physiotherapist, occupational therapist, and speech therapist
Routine chest physiotherapy and mechanical insufflator‐exsufflator device
Consider antacids, H2 blockers or PPI if GERD present
Consider gastrostomy tube and fundoplication if severe GERD/aspiration present
Consider adenoidectomy/tonsillectomy if obstructive sleep apnea present
Consider continuous nighttime pulse oximetry depending on sleep study results
Consider nighttime noninvasive ventilation depending on sleep study results
Use sedatives with caution given reports of prolonged effects in this patient population
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affected family members (PP1). In this context, it should be noted
that large deletions spanning the whole TECPR2‐gene, in the homo-
zygous state or in trans with another pathogenic variant, would re-
duce the gene dosage and be consequently classified as pathogenic.
This also applies to intragenic duplications disrupting the TECPR2
reading frame (cf. Supporting Information File S2 sheet “allClinVar”).
However, large duplications encompassing all of TECPR2 are not
expected to disrupt the reading frame and should be evaluated ac-
cording to the above recommendations for missense variants and
followed up functionally (e.g., expression analyses on RNA level).
Our estimation of the carrier frequency is based on automated
ACMG classification of variants and therefore includes only poten-
tially truncating variants. Given that eight of the 17 unique variants
are missense variants and considering a large number of un-
characterized TECPR2 missense variants (729 in gnomAD and 448 in
BRAVO), we anticipate that the true carrier frequency for (likely)
pathogenic TECPR2‐variant might be double our current estimate of
0.082% in the general population. Notably, the estimated carrier
frequency is 7.9× higher (0.650%) in individuals with Jewish
Ashkenazi background and at least 16.2× higher (1.33%) with Jewish
Bukharian background (Oz‐Levi et al., 2012). A review of carrier
screening tests for individuals of Jewish descent showed that
TECPR2 is currently included in four offered tests (see Table S1).
Overall, based on these high carrier frequencies, both founder var-
iants should be included in commercial carrier screening tests to
inform genetic counseling and diagnostics in Jewish couples at in-
creased risk for children with TECPR2‐associated disease.
TECPR2 encodes a protein that is implicated in the early steps of
the autophagy pathway where it interacts with the Atg8 family
proteins, including LC3, to promote autophagic vesicle formation
(Behrends et al., 2010). Fibroblasts from affected individuals showed
a decreased number of autophagosomes and reduced delivery of LC3
and p62 for lysosomal degradation; this suggests an impairment of
autophagic flux (Oz‐Levi et al., 2012). Providing insights into the
mechanism of defective autophagy, a subsequent study showed that
TECPR2 is involved in maintaining functional endoplasmic reticulum
exit sites, which are implicated in the cargo from the endoplasmic
reticulum to Golgi and may serve as scaffolds for the formation of
autophagosomes (Stadel et al., 2015).
While the precise role of autophagy in TECPR2‐associated
disease remains to be established, there are several clinical fea-
tures that are shared with other single‐gene disorders of this
pathway (Ebrahimi‐Fakhari et al., 2016; Teinert et al., 2019). This
includes the involvement of multiple brain areas, clinical signs that
point to a progressive involvement of the long central nervous
system tracts, such as the corticospinal tracts, as well as the
imaging finding of a thinning of the corpus callosum. TECPR2‐
associated disease, however, stands out for its prominent in-
volvement of brain stem function, autonomic dysregulation, and
peripheral neuropathy.
In summary, our cross‐sectional analysis provides a depiction of
clinical and molecular features across the age spectrum. Functional
analyses of the variant mechanisms are of great importance to
confirm the intended effect by our in silico modeling approach. Fu-
ture prospective longitudinal studies to better define the natural
history and patterns of disease progression are required. Our pre-
sent study provides a framework for assessing disease manifesta-
tions. Close follow‐up and surveillance for neurological and non‐
neurological manifestations are recommended.
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